Rab7 silencing prevents μ-opioid receptor lysosomal targeting and rescues opioid responsiveness to strengthen diabetic neuropathic pain therapy

Diabetes

Volumn 62, Issue 4, 2013, Pages 1308-1319

  Mousa, Shaaban A ^a   Shaqura, Mohammed ^a   Khalefa, Baled I ^a   Zöllner, Christian ^b   Schaad, Laura ^a   Schneider, Jonas ^a   Shippenberg, Toni S ^c   Richter, Jan F ^a   Hellweg, Rainer ^a   Shakibaei, Mehdi ^d   Schäfer, Michael ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^d UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN GENE RELATED PEPTIDE; FENTANYL; G PROTEIN COUPLED RECEPTOR; GLUCOSE; MU OPIATE RECEPTOR; NALOXONE; NERVE GROWTH FACTOR; RAB7 PROTEIN; SMALL INTERFERING RNA;

ANALGESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CELL DENSITY; CELL MEMBRANE; CONTROLLED STUDY; DIABETIC NEUROPATHY; DRUG EFFICACY; DRUG TARGETING; GENE SILENCING; GLUCOSE BLOOD LEVEL; HYPERALGESIA; LYSOSOME; NERVE FIBER; NEUROPATHIC PAIN; NONHUMAN; PAIN THRESHOLD; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSORY NERVE CELL; STREPTOZOCIN DIABETES; WEIGHT GAIN;

ANALGESICS, OPIOID; ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEUROPATHIES; FENTANYL; GENE SILENCING; HYPERALGESIA; LYSOSOMES; MALE; PAIN MEASUREMENT; PROTEIN TRANSPORT; RAB GTP-BINDING PROTEINS; RATS; RATS, WISTAR; RECEPTORS, OPIOID, MU; RNA, SMALL INTERFERING; WEIGHT GAIN;

EID: 84875438596     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db12-0590     Document Type: Article

References (46)

1. Boulton AJM, Vinik AI, Arezzo JC, Bril V, Feldman EL, Freeman R, Malik RA, Maser RE, Sosenko JM, Ziegeler D. Diabetic neuropathies: A statement by the American Diabetes Association. Diabetes Care 2004;28:956-962
2. Harati Y, Gooch C, Swenson M, et al. Maintenance of the long-term effectiveness of tramadol in treatment of the pain of diabetic neuropathy. J Diabetes Complications 2000;14:65-70
3. Watson CP, Moulin D, Watt-Watson J, Gordon A, Eisenhoffer J. Controlledrelease oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. Pain 2003;105:71-78
4. Dworkin RH, O'Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010;85(Suppl):S3-S14
5. Annemans L. Pharmacoeconomic impact of adverse events of long-term opioid treatment for the management of persistent pain. Clin Drug Investig 2011;31:73-86
6. Courteix C, Bourget P, Caussade F, et al. Is the reduced efficacy of morphine in diabetic rats caused by alterations of opiate receptors or of morphine pharmacokinetics? J Pharmacol Exp Ther 1998;285:63-70
7. Chen SR, Pan HL. Antinociceptive effect of morphine, but not mu opioid receptor number, is attenuated in the spinal cord of diabetic rats. Anesthesiology 2003;99:1409-1414
8. Zurek JR, Nadeson R, Goodchild CS. Spinal and supraspinal components of opioid antinociception in streptozotocin induced diabetic neuropathy in rats. Pain 2001;90:57-63
9. Chen SR, Sweigart KL, Lakoski JM, Pan HL. Functional mu opioid receptors are reduced in the spinal cord dorsal horn of diabetic rats. Anesthesiology 2002;97:1602-1608
10. Shangguan Y, Hall KE, Neubig RR, Wiley JW. Diabetic neuropathy: inhibitory G protein dysfunction involves PKC-dependent phosphorylation of Goalpha. J Neurochem 2003;86:1006-1014
11. Mousa SA, Cheppudira BP, Shaqura M, et al. Nerve growth factor governs the enhanced ability of opioids to suppress inflammatory pain. Brain 2007; 130:502-513
12. Stein C, Schäfer M, Machelska H. Attacking pain at its source: new perspectives on opioids. Nat Med 2003;9:1003-1008
13. Gaveriaux-Ruff C, Nozaki C, Nadal X, et al. Genetic ablation of delta opioid receptors in nociceptive sensory neurons increases chronic pain and abolishes opioid analgesia. Pain 2011;152:1238-1248
14. Zöllner C, Mousa SA, Fischer O, et al. Chronic morphine use does not induce peripheral tolerance in a rat model of inflammatory pain. J Clin Invest 2008;118:1065-1073
15. Truong W, Cheng C, Xu QG, Li XQ, Zochodne DW. Mu opioid receptors and analgesia at the site of a peripheral nerve injury. Ann Neurol 2003;53: 366-375
16. Yuyama K, Yanagisawa K. Late endocytic dysfunction as a putative cause of amyloid fibril formation in Alzheimer's disease. J Neurochem 2009;109: 1250-1260
17. Yamdeu RS, Shaqura M, Mousa SA, Schäfer M, Droese J. p38 Mitogenactivated protein kinase activation by nerve growth factor in primary sensory neurons upregulates m-opioid receptors to enhance opioid responsiveness toward better pain control. Anesthesiology 2011;114:150-161
18. Davidson E, Coppey L, Lu B, Arballo V, Calcutt NA, Gerard C, Yorek M. The roles of streptozotocin neurotoxicity and neutral endopeptidase in murine diabetic neuropathy. Exp Diabetes Res 2009:431980 Epub 2010 Feb 3.
19. Cahill CM, Dray A, Coderre TJ. Intrathecal nerve growth factor restores opioid effectiveness in an animal model of neuropathic pain. Neuropharmacology 2003;45:543-552
20. Luo MC, Zhang DQ, Ma SW, et al. An efficient intrathecal delivery of small interfering RNA to the spinal cord and peripheral neurons. Mol Pain 2005; 1:29
21. Endres-Becker J, Heppenstall PA, Mousa SA, et al. Mu-opioid receptor activation modulates transient receptor potential vanilloid 1 (TRPV1) currents in sensory neurons in a model of inflammatory pain. Mol Pharmacol 2007;71:12-18
22. Shaqura MA, Zöllner C, Mousa SA, Stein C, Schäfer M. Characterization of mu opioid receptor binding and G protein coupling in rat hypothalamus, spinal cord, and primary afferent neurons during inflammatory pain. J Pharmacol Exp Ther 2004;308:712-718
23. Romero Rosales K, Peralta ER, Guenther GG, Wong SY, Edinger AL. Rab7 activation by growth factor withdrawal contributes to the induction of apoptosis. Mol Biol Cell 2009;20:2831-2840
24. Hellweg R, Lohmann P, Huber R, Kühl A, Riepe MW. Spatial navigation in complex and radial mazes in APP23 animals and neurotrophin signaling as a biological marker of early impairment. Learn Mem 2006;13:63-71
25. Zhao H, Laitala-Leinonen T, Parikka V, Väänänen HK. Downregulation of small GTPase Rab7 impairs osteoclast polarization and bone resorption. J Biol Chem 2001;276:39295-39302
26. Mousa SA, Shaqura M, Schäper J, et al. Identification of mu-and kappaopioid receptors as potential targets to regulate parasympathetic, sympathetic, and sensory neurons within rat intracardiac ganglia. J Comp Neurol 2010;518:3836-3847
27. Yao X, Liu J, McCabe JT. Ubiquitin and ubiquitin-conjugated protein expression in the rat cerebral cortex and hippocampus following traumatic brain injury (TBI). Brain Res 2007;1182:116-122
28. Damke H, Baba T, Warnock DE, Schmid SL. Induction of mutant dynamin specifically blocks endocytic coated vesicle formation. J Cell Biol 1994; 127:915-934
29. Brack A, Rittner HL, Machelska H, et al. Control of inflammatory pain by chemokine-mediated recruitment of opioid-containing polymorphonuclear cells. Pain 2004;112:229-238
30. Mousa SA, Shakibaei M, Sitte N, Schäfer M, Stein C. Subcellular pathways of beta-endorphin synthesis, processing, and release from immunocytes in inflammatory pain. Endocrinology 2004;145:1331-1341
31. Ohsawa M, Kamei J. Modification of kappa-opioid receptor agonistinduced antinociception by diabetes in the mouse brain and spinal cord. J Pharmacol Sci 2005;98:25-32
32. Zochodne DW, Verge VM, Cheng C, Sun H, Johnston J. Does diabetes target ganglion neurones? Progressive sensory neurone involvement in long-term experimental diabetes. Brain 2001;124:2319-2334
33. Piper RC, Katzmann DJ. Biogenesis and function of multivesicular bodies. Annu Rev Cell Dev Biol 2007;23:519-547
34. Hanyaloglu AC, von Zastrow M. Regulation of GPCRs by endocytic membrane trafficking and its potential implications. Annu Rev Pharmacol Toxicol 2008;48:537-568
35. Thibault D, Albert PR, Pineyro G, Trudeau LÉ. Neurotensin triggers dopamine D2 receptor desensitization through a protein kinase C and b-arrestin1-dependent mechanism. J Biol Chem 2011;286:9174-9184
36. Leterrier C, Bonnard D, Carrel D, Rossier J, Lenkei Z. Constitutive endocytic cycle of the CB1 cannabinoid receptor. J Biol Chem 2004;279:36013-36021
37. Ceresa BP, Bahr SJ. rab7 activity affects epidermal growth factor:epidermal growth factor receptor degradation by regulating endocytic trafficking from the late endosome. J Biol Chem 2006;281:1099-1106
38. Martini L, Waldhoer M, Pusch M, et al. Ligand-induced down-regulation of the cannabinoid 1 receptor is mediated by the G-protein-coupled receptorassociated sorting protein GASP1. FASEB J 2007;21:802-811
39. Bucci C, Thomsen P, Nicoziani P, McCarthy J, van Deurs B. Rab7: a key to lysosome biogenesis. Mol Biol Cell 2000;11:467-480
40. Vanlandingham PA, Ceresa BP. Rab7 regulates late endocytic trafficking downstream of multivesicular body biogenesis and cargo sequestration. J Biol Chem 2009;284:12110-12124
41. Balut CM, Gao Y, Murray SA, Thibodeau PH, Devor DC. ESCRT-dependent targeting of plasma membrane localized KCa3.1 to the lysosomes. Am J Physiol Cell Physiol 2010;299:C1015-C1027
42. Li J, Chen C, Huang P, Liu-Chen LY. Inverse agonist up-regulates the constitutively active D3.49(164)Q mutant of the rat mu-opioid receptor by stabilizing the structure and blocking constitutive internalization and down-regulation. Mol Pharmacol 2001;60:1064-1075
43. Apfel SC. Nerve growth factor for the treatment of diabetic neuropathy: what went wrong, what went right, and what does the future hold? Int Rev Neurobiol 2002;50:393-413
44. Kanbayashi H, Itoh H, Kashiwaya T, Atoh K, Makino I. Spatial distribution of nociceptive neuropeptide and nerve growth factor depletion in experimental diabetic peripheral nervous system. J Int Med Res 2002;30:512-519
45. Sasaki K, Chancellor MB, Phelan MW, et al. Diabetic cystopathy correlates with a long-term decrease in nerve growth factor levels in the bladder and lumbosacral dorsal root Ganglia. J Urol 2002;168:1259-1264
46. Cattaneo A. Tanezumab, a recombinant humanized mAb against nerve growth factor for the treatment of acute and chronic pain. Curr Opin Mol Ther 2010;12:94-106